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Abstract
Background. Atypical teratoid/rhabdoid tumors (ATRTs) are known to exhibit molecular and clinical heteroge-
neity even though SMARCB1 inactivation is the sole recurrent genetic event present in nearly all cases. Indeed, 
recent studies demonstrated 3 molecular subgroups of ATRTs that are genetically, epigenetically, and clinically 
distinct. As these studies included different numbers of tumors, various subgrouping techniques, and naming, 
an international working group sought to align previous findings and to reach a consensus on nomenclature and 
clinicopathological significance of ATRT subgroups.
Methods. We integrated various methods to perform a meta-analysis on published and unpublished DNA methyl-
ation and gene expression datasets of ATRTs and associated clinicopathological data.
Results. In concordance with previous studies, the analyses identified 3 main molecular subgroups of ATRTs, for 
which a consensus was reached to name them ATRT-TYR, ATRT-SHH, and ATRT-MYC. The ATRT-SHH subgroup ex-
hibited further heterogeneity, segregating further into 2 subtypes associated with a predominant supratentorial 
(ATRT-SHH-1) or infratentorial (ATRT-SHH-2) location. For each ATRT subgroup we provide an overview of its main 
molecular and clinical characteristics, including SMARCB1 alterations and pathway activation.
Conclusions. The introduction of a common classification, characterization, and nomenclature of ATRT subgroups 
will facilitate future research and serve as a common ground for subgrouping patient samples and ATRT models, 
which will aid in refining subgroup-based therapies for ATRT patients.
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Key Points
1. Meta-analyses confirmed the presence of 3 distinct molecular subgroups of ATRT.
2.   Consensus was reached to name them ATRT-TYR, ATRT-SHH, and ATRT-MYC
3.   Overview is presented of molecular and clinical characteristics of each subgroup.
Atypical teratoid/rhabdoid tumors (ATRTs) arise in all 
compartments of the central nervous system (CNS), pre-
dominantly affect infants or young children, and display a 
remarkably simple cancer genome. Biallelic mutation—in-
cluding partial or whole loss of chromosome 22, resulting 
in inactivation of SWItch/sucrose nonfermentable (SWI/
SNF) related, matrix associated, actin dependent regu-
lator of chromatin, subfamily B1 (SMARCB1)—is the main, 
and often only, recurrent molecular feature seen in ATRT.1 
Rare cases (<5%) with an intact SMARCB1 harbor muta-
tions in SMARCA4, both encoding components of the SWI/
SNF chromatin remodeling complex.2,3 The recurrent loss 
of SMARCB1 in these tumors is in stark contrast to a ple-
omorphic histology and considerable molecular and clin-
ical heterogeneity observed in ATRT cohorts. Therapeutic 
strategies in ATRT are largely influenced by the age of the 
patient, tumor location in the CNS, and disease stage at 
diagnosis.4 These factors inform extent of surgical resec-
tion and various radiological and chemotherapeutic inter-
ventions. However, there is currently no international 
consensus on standard therapeutic approaches, with the 
majority of therapeutic and survival data being published 
on a center-by-center basis. Numbers of patients with 
ATRT are small, therefore concerted international efforts to 
evaluate and standardize therapy are ongoing. However, it 
is as yet unclear how tumor biology shapes the response 
to treatment, outcome, and/or long-term effects in patients 
with ATRT. A critical step toward improving the poor out-
look for these patients is therefore to define and charac-
terize the biological heterogeneity in ATRT such that a 
standard subgrouping scheme is available and can be fur-
ther used to investigate subgroup-specific features of ATRT 
and inform subgroup-specific therapies.
Earlier attempts to subgroup ATRT at the transcriptomic 
level had already recognized a degree of heterogeneity but 
were limited by a small cohort size.5 More recently, inter-
national efforts to collect and profile significantly larger co-
horts of ATRTs have resulted in the identification of distinct 
ATRT subgroups defined by gene expression and/or DNA 
methylation profiling and associated with different mo-
lecular and clinicopathological features (Table 1).6–8 Since 
the number of subgroups and platforms used to identify 
these subgroups differed between studies, there is an ur-
gent need to align findings and define the number, molec-
ular and clinical features, and a common nomenclature for 
ATRT subgroups.
To this end, we performed a meta-analysis of previously 
published and additional ATRT DNA methylation profiles 
with parallel transcriptomic and clinicopathological data in 
order to generate a consensus definition and naming for 
ATRT subgroups and to define their main molecular and 
clinicopathological characteristics.
Materials and Methods
Integrated Analyses of ATRT Profiling Data
Due to the variety of data types and platforms used pre-
viously to subgroup ATRT, we first created a composite 
dataset of all cases (n = 388), profiled using the Illumina 
Infinium HumanMethylation 450K or EPIC array. We ex-
cluded all samples (n =  5) that were either duplicates or 
relapse cases. To exclude cases with a low tumor con-
tent or outliers for which a high-confidence classification 
of ATRT could not be achieved, we removed all samples 
(n = 58) with a calibrated score <0.9 using the Heidelberg 
brain tumor classifier published by Capper et  al9 (www.
molecularneuropathology.org). This filtering step aimed 
to identify potential outlier samples and generated a high-
quality reference dataset for classification of subgroups. 
A number of factors could contribute to a sample failing to 
be classified as ATRT with high confidence, including high 
nonneoplastic cell content and low-quality tumor material 
from archival samples.
Of the remaining 325 samples, 137 had been pub-
lished by Johann et  al8 and 96 by Torchia et  al,7 and 92 
are newly added unpublished samples from the Northern 
Institute of Cancer Research (Newcastle University) (Gene 
Expression Omnibus [GEO] accession no. GSE141363) 
and the EURHAB study (GEO accession no. GSE141039) 
(Supplementary Table 1). Informed consent was obtained 
for all cases. In order to determine consensus subgroups, 
Importance of the Study
The international consensus on number and naming 
of ATRT molecular subgroups and their main charac-
teristics, which we present here, will be important for 
the design of future clinical trials, patient stratification, 
and a uniform classification of patients’ tumor samples, 
much in line as it has been for medulloblastoma, 
ependymoma, and high-grade glioma. It will also be 
essential for a better interpretation of preclinical ex-
periments using properly classified in vitro and in vivo 
ATRT models.
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methylation array data were subjected to 3 different clus-
tering methods, including consensus nonnegative matrix 
factorization (NMF),10 regular NMF,6,7 and unsupervised 
consensus clustering8 (see Supplementary Methods for 
full technical details). Algorithms chosen had either been 
previously applied to discover ATRT subgroups or used in 
consensus subgrouping studies for other CNS tumors (ie, 
medulloblastoma [MB]11).
Consensus calls were established by comparison 
of calls from the 3 different methods, and consensus 
subgrouping was based on at least equivalent calls from 
2 of the 3 methods. A “no consensus call” was assigned 
in 4 cases. As an additional validation step, we corrob-
orated consensus calls using t-distributed stochastic 
neighbor embedding (t-SNE) analysis of the consensus 
dataset.
To corroborate DNA methylation–based classification, 
we also reanalyzed published Affymetrix HG-U133 Plus 
2.0 expression profiles (n =  97)8,12 and Illumina HT12 v4 
gene expression array data (n = 60)6 (see Supplementary 
Methods for further information).
Results
DNA Methylation and Gene Expression Profiling 
Identify 3 Main Subgroups of ATRT
Robust DNA methylation data from 325 unique ATRT 
cases (Fig.   1) were classified using 3 independent 
clustering algorithms (consensus NMF, regular NMF, 
ConsensusClusterPlus) to define consensus subgroups of 
ATRTs. Each method was applied considering a number of 
possible subgroups between 2 and 8.  Clustering metrics 
(including but not limited to cophenetic coefficients, change 
in area under the cumulative distribution function curve, 
dispersion, kappa, silhouette score; Supplementary Fig.  1) 
indicated that the most consistently robust clustering so-
lution was 3 subgroups with possible further subclusters 
identified, as previously discussed by Johann et  al,8 but 
supported less robustly here (Fig.  2, Supplementary Fig. 
1). There was very high concordance between subgrouping 
based on consensus clustering (97%, 316 cases correctly 
classified), NMF (98%, 318 cases correctly classified), and 
consensus NMF (99%, 321 cases correctly classified), as 
shown in the Sankey plot in Fig.  2C. Notably, adding back 
samples excluded for low classification calls did not alter 
number of subgroups, as indicated in the t-SNE analysis 
and cluster metrics for the methylation array analyses 
(Supplementary Fig.  2).
Given that each clustering method consistently iden-
tified 3 main subgroups of ATRTs, with a high degree 
(>90%) of concordance between the different methods 
applied (Fig.  2), we chose this as the basis of our con-
sensus subgrouping. As shown in Fig.  2A, B, Group 1 an-
notated cases from the Torchia et  al study7 formed one 
group with the ATRT-SHH cases from the Johann et  al 
study,8 while Group  2A or Group  2B annotated cases 
form groups with either ATRT-TYR or ATRT-MYC cases, 
respectively, indicating that our previous studies identi-
fied largely the same 3 subgroups. We have designated 
the 3 subgroups as ATRT-SHH, ATRT-TYR, and ATRT-MYC, 
based on the nomenclature proposed by Johann et al.8
We next analyzed ATRT gene expression profiles avail-
able for a total of 172 cases, profiled on Affymetrix 
HG-U133 Plus 2.0 arrays (112, including 15 new cases) or 
Illumina HT-12 v4 arrays (60 cases).6 For 21 Affymetrix cases 
and for 48 Illumina profiled tumors there were matching 
DNA methylation data. Unsupervised hierarchical clus-
tering analysis of the Affymetrix data using expression of 
the 1500 most variable genes confirmed the presence of 
3 major molecular subgroups of ATRTs in line with DNA 
methylation analyses (Fig.   3A). These results remained 
stable across different numbers of differentially expressed 
genes (data not shown). Subgroup annotations were also 
highly concordant with prior publications where subsets 
of these data have been analyzed8,12; annotated cases of 
human intracranial 1 (hIC1) largely overlapped with the 
ATRT-SHH cases (8/10), while hIC2 and hIC3 annotated 
  
Table 1. Summary of defining transcriptional features of ATRT subgroups. Data derived from publications8–10 
Study Subgroups Methods/Platforms Used  
(n = # cases)
Torchia 
et al, 2015
Group 1  
Overexpression of 
ASCL1
Group 2 Immunohistochemistry 
(ASCL1) (n = 170)   
Gene expression array pro-
filing (IIlumina HT12) (n = 43)
Torchia 
et al, 2016
Group 1  
Overexpression of 
Notch pathway genes 
ASCL1, CBL, HES1
Group 2A Overexpression of  
neuronal and mesenchymal genes  
OTX2, PDGFRB, BMP4
Group 2B  
Overexpression of  
HOX cluster genes
Methylation array profiling 
(Illumina 450K) (n = 162)   
Gene expression array pro-
filing (IIlumina HT12) (n = 90)
Johann 
et al, 2016
ATRT-SHH 
Overexpression of  
SHH pathway genes 
GLI2, BOC, PTCHD2, 
MYCN
ATRT-TYR Overexpression of  
melanosomal genes TYR,  
TYRP, MITF, OTX2
ATRT-MYC  
Overexpression of  
MYC and HOX  
cluster genes
Methylation array profiling 
(Illumina 450K) (n = 150)   
Gene expression array  
profiling (Affymetrix U133 
Plus 2.0) (n = 69)
Han et al, 
2016
hIC2 Overexpression 
of ASCL1, BOC, SOX2, 
GLI2, FABP7
hIC1 Overexpression of BMP4,  
OTX2, SMAD7
hIC3 Overexpression of 
ACTL6A, FABP7, GFAP
Gene expression array  
profiling (Affymetrix U133 
Plus 2.0) (n = 30)
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cases largely overlapped with ATRT-TYR cases (10/12) 
and ATRT-MYC cases (5/5), respectively (Fig.  3A). For the 
21 cases with matched Affymetrix gene expression and 
DNA methylation data there was also good concordance, 
with only 2 samples annotated to different subgroups. 
We assigned final annotation of these 2 cases based on 
the DNA methylation data. Similarly, unsupervised hier-
archical clustering of the Illumina gene expression data 
also revealed 3 molecular subgroups of ATRTs with a good 
concordance (96%) between DNA methylation array and 
Illumina based subgrouping (Supplementary Fig.  3). It is 
worth noting that the clustering metrics derived from the 
Affymetrix data also supported 3 main and not additional 
subgroups (Supplementary Fig.  4B).
Finally, in order to gain further insights into the biology of 
the subgroups, we performed ingenuity pathway and gene 
set enrichment analyses, for which the normalized enrich-
ment scores are shown in Fig.  3B as a radar plot. Overall, 
the ATRT-SHH subgroup displayed a low overlap of en-
riched gene sets with ATRT-TYR and ATRT-MYC, but there 
was some overlap between ATRT-TYR and ATRT-MYC—in 
particular for gene sets related to immune response. The 
specific gene enrichment features as well as comments on 
known published genes for each subgroup are described 
below.
Molecular and Clinical Features of the 3 
Subgroups
Having identified and confirmed the presence of 3 main 
molecular subgroups of ATRTs, we examined available 
pooled molecular and clinicopathological data of all cases 
to define the main characteristics of each group as de-
scribed below and shown in Fig.  4 (and an overview of cy-
togenetic aberrations is in Supplementary Fig.  5).
Correlations of the 3 Subgroups with Published 
ATRT Models
In the last years, a number of cell lines and genetically engin-
eered mouse models have been established to model ATRT 
tumorigenesis. In order to see how these match our con-
sensus human ATRT subgrouping, we collected RNAseq and 
gene expression data from previously published studies12–14 
and performed a multidimensional scaling (MDS) analysis, 
sample-wise correlation between cell lines and mouse models 
against human ATRT samples (Supplementary Fig.  6A, C), 
and unsupervised hierarchical clustering analysis on the com-
bined human and mouse datasets using orthologous genes 
(Supplementary Fig.  6B). Results of this preclinical model char-
acterization are discussed below in the respective sections.
  
Methylation array
388 samples
325 samples representing the consensus set
Consensus
clustering NMF NMF+KM HCL NMF
Expression subgroup
assignment
Pathway analysis
112  Affymetrix HG-U133 Plus 2.0
60    Illumina HT-12 v4
Gene expression array
58      samples
5        samples
Excluded samples
MNP score < 0.9:
Duplicates:
Final methylation subgroup
assignment
Based on consensus call:
113    ATRT-TYR
134    ATRT-SHH
74      ATRT-MYC
4        Samples with no consensus
Fig.  1 Overview flow charts on all analyses and samples.  
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ATRT-TYR
The ATRT-TYR subgroup was named after the enzyme 
tyrosinase, which is highly overexpressed in most 
ATRT-TYR cases, but not in the other ATRT subgroups 
or other brain tumors, indicating it may be a good di-
agnostic marker for ATRT-TYR cases.15 The protein 
physiologically catalyzes the synthesis of melanin in 
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Fig.  2 Methylation array analysis of the consensus dataset. (A) Unsupervised hierarchical clustering using the top 5000 most variable cytosine-guanine 
(CG) sites confirms the presence of 3 subgroups in the consensus dataset (325 samples). (B) t-SNE visualization of the analyzed dataset based on the 5000 
most variable CG sites reproduces segregation into 3 main ATRT subgroups. Coloring of data points in the t-SNE plots displays the subgrouping as published 
by Johann et al8 (upper plot) or by Torchia et al7 (lower plot). Half transparent circles show the consensus subgroups used in this paper. (C) Sankey plot 
displaying the concordance between the subgroup calls using different methods (NMF, consensus clustering, and NMF + k-means based subgrouping). 
Numbers in each subgroup show the number of samples which have been assigned to the subgroup with the respective method.  
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melanocytes and is an important protagonist in neural 
tube development.16 Although the role of TYR in ATRT 
tumorigenesis remains to be established, it is notable 
that several other components of the melanosomal 
pathway, including the tyrosinase-related protein TYRP 
and the melanoma-oncogene MITF, are also upregulated 
in this subgroup, potentially reflecting restricted 
neuroectodermal origins.17
Other pathways and genes upregulated in ATRT-TYR 
tumors include the bone morphogenetic protein (BMP) 
pathway (eg, BMP4) and developmentally related tran-
scription factors such as orthodenticle homeobox 2 (OTX2) 
(Supplementary Fig.  4A). Gene set enrichment analysis 
performed on the differentially overexpressed genes con-
firms the melanosomal pathway and tyrosine metabo-
lism (Fig.   3B, “GO [developmental] Pigmentation,” “GO 
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Fig.  3 Cluster analysis based on Affymetrix array gene expression data. (A) Unsupervised hierarchical clustering using the top 1500 most vari-
able genes in the consensus gene expression dataset. Annotations in the lower bar show the grouping as presented by Han et al12 and by Johann 
et al8 and the current methylation consensus calls. (B) Visualization of gene set enrichment analysis results as a radar plot. Axis displays the 
normalized enrichment values. Each ATRT subgroup is represented in the respective subgroup color.
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Pigment granule organization”), as well as epithelial prolif-
eration as being enriched in ATRT-TYR (Fig.  3B). Although 
comprehensive histopathological studies of ATRT molec-
ular subtypes remain pending, it is notable that cribriform 
neuroectodermal tumors (CRINETs), which also all express 
TYR, have DNA methylation profiles that are highly similar 
to ATRT-TYR tumors,18 suggesting that CRINET and ATRT-
TYR tumors may represent 2 histological variants with a 
common cell of origin. Whether the favorable outcomes of 
CRINET patients18 also apply to patients with ATRT-TYR tu-
mors remains to be investigated.
Genetically, the prototypic type of biallelic SMARCB1 
inactivation in the ATRT-TYR group is whole or partial 
loss of one copy of chromosome 22 accompanied by an 
inactivating (eg, point) mutation in SMARCB1 on the 
other allele (Fig.  4C, D). The loss of chromosome 22 was 
more prevalent in ATRT-TYR (86 vs 59 cases in ATRT-SHH 
and 16 cases in ATRT-MYC; P  =  0.053, chi-square test). 
Investigations using assay for transposase-accessible 
chromatin sequencing revealed that this subgroup har-
bors a more open chromatin, suggestive of a more prim-
itive epigenetic landscape compared with the other ATRT 
subgroups.7
Clinically, ATRT-TYR patients represent the youngest pa-
tient group, with median age at diagnosis of 12  months 
(range, 0–108 mo). This subgroup also contained the 
highest proportion of patients under 3  years of age at 
time of diagnosis (90% in ATRT-TYR vs 74.6% in ATRT-SHH 
vs 52.3% in ATRT-MYC; Fig.  4A, Supplementary Table 1). 
Most (75%, 52 of 69 with location data) ATRT-TYR tumors 
have infratentorial location, and only 25% (17 cases) are 
located supratentorially (Fig.  4B). This differs significantly 
from ATRT-SHH and ATRT-MYC, which are more often lo-
calized supratentorially (P = 2.21e-09, chi-square test). A re-
cent radiogenomics study of ATRT molecular subgroups 
suggested that ATRT-TYR tumors may have MRI appear-
ance characterized by a bandlike enhancement of contrast 
media.19
For preclinical studies, the number of available in vitro 
and in vivo models for ATRT remains very limited, and 
the number of models with molecular subgroup informa-
tion is even more limited. In a recently published study 
by Brabetz et al,20 3 ATRT patient xenograft models from 
the SHH and MYC subgroups were included, but none of 
the analyzed xenografts exhibited the profile of ATRT-TYR. 
The study by Torchia et al7 classified 8 ATRT cell lines as 3 
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representing Group 1 (equivalent to ATRT-SHH) and 5 rep-
resenting Group  2 (equivalent to ATRT-TYR/ATRT-MYC). 
However, so far it has remained unclear how many of 
the Group 2 cell lines represent ATRT-TYR (Group 2A) tu-
mors and how many represent ATRT-MYC (Group  2B). 
Aiming to answer this question, we have analyzed the 
available transcriptomic data for these cell lines. For 
CHLA02, CHLA04, and CHLA05 the allocation to the ATRT-
SHH subgroup is confirmed as expected by unsuper-
vised hierarchical clustering and visualized in the MDS 
plot (Supplementary Fig.  6). For the remaining cell lines 
(BT12, BT16, SH, CHLA266, CHLA06), allocation to either 
ATRT-TYR or ATRT-MYC has so far not been performed. 
Projection from the MDS plot, correlation analysis, and un-
supervised clustering (Supplementary Fig.  6A–C) indicate 
that BT12, BT16, CHLA06, CHL266, and SH can clearly be 
allocated to ATRT-MYC. These 5 cell lines, previously char-
acterized as Group 2, all exhibited high expression of MYC 
and elevated HOX gene expression in some, but all lacked 
the TYR group signature (see Supplementary Fig.  6D). 
Taken together, these data suggest that these cell lines are 
likely all derived from ATRT-MYC tumors.
Additional models have been employed in several other 
publications investigating drug targets in ATRT xenografts, 
but the subgroup identity of these models remains unknown. 
In the cell line BT37, for instance, the role of high-mobility 
group adenine thymine–hook 2 (HMGA2) as an oncogene 
has been highlighted.21 This protein is overexpressed specif-
ically in ATRT-TYR (Supplementary Fig.  4), suggesting that 
BT37 may represent an ATRT-TYR model. While numerous 
studies have examined drug targets in ATRT irrespective 
of their subgroup, knowledge of subgroup-specific vulner-
abilities is sparse. Platelet derived growth factor receptor B 
(PDGFRB), for example, has been shown to be a drug target 
in Group 2 cell lines BT12, BT16, CHLA266, CHLA06, and SH, 
and they all displayed a higher susceptibility to the PDGFRB 
inhibitors nilotinib and dasatinib than did Group 1 (ATRT-SHH) 
cell lines. Again, whether this means that both ATRT-TYR and 
ATRT-MYC tumors can be targeted by these inhibitors remains 
to be seen, as PDGFRB expression levels in ATRT-TYR tumors 
are much higher than in ATRT-MYC tumors (Supplementary 
Fig.  4). Transcriptome analyses further suggest other prom-
ising drug targets that have or have not been tested already 
in rhabdoid tumors. For instance, fibroblast growth factor re-
ceptor 2 (FGFR2) is specifically upregulated in ATRT-TYR, and 
FGFR signaling (together with PDGFR inhibition) has been 
described as a vulnerability in rhabdoid tumors.22,23 Another 
possible candidate is Janus kinase 1 (JAK1), a protein tyrosine 
kinase overexpressed in ATRT-TYR that regulates the signaling 
cascade of JAK–signal transducers and activators of tran-
scription (STAT). Approved inhibitors such as ruxolitinib are 
available and hold the promise of a possible targeted therapy. 
Further drug screening using robustly subgrouped cell lines 
will be important to determine which of the prior preclinically 
tested substances have subgroup specificity.
ATRT-SHH
The ATRT-SHH subgroup, in the Torchia et  al publication 
also referred to as Group 1,7 displays an overexpression 
of both sonic hedgehog (SHH) and Notch pathway 
members, such as GLI2, PTCH1, and BOC (all SHH 
pathway) or ASCL1, HES1, DTX1 (all regulators of the 
Notch pathway; Supplementary Fig.  4A). Protein expres-
sion of achaete-scute homolog 1 (ASCL1), a neuronal 
differentiation transcription factor, has been suggested 
as an immunohistochemical marker for this subgroup.6 
Moreover, Torchia et  al6 showed that ASCL1 protein ex-
pression could be a biomarker for improved survival, 
suggesting that ASCL1-positive ATRT-SHH (Group  1) 
cases have a better overall survival than ASCL1-negative 
(Group  2) ATRTs.6 However, as ASCL1 is not expressed 
in all samples of the SHH subgroup and can also be ex-
pressed in some cases of the other subgroups, it remains 
to be seen whether patients with ATRT-SHH tumors have a 
better outcome than other ATRT patients. More analyses 
on prospective cohorts of ATRT patients are needed to see 
whether there are survival differences between the 3 mo-
lecular subgroups defined by DNA methylation.
Beyond the oncogenic signaling pathways, gene set en-
richment analyses confirmed previous observations that 
ATRT-SHH is mainly a neuronally differentiated subgroup 
with enrichment of genes involved in “axon guidance path-
ways” and “neuronal system” pathways compared with 
other subgroups (Fig.  3B).
Torchia et al showed using small interfering RNA and 
gamma secretase inhibitors that the Group  1/SHH cell 
lines depended on Notch signaling for growth.7 However, 
therapeutic significance of SHH signaling for ATRT-SHH 
remains to be tested, as unlike SHH-activated MBs in the 
MB-SHH subgroup, genomic aberrations of SHH pathway 
members including PTCH1, SMO, and SUFU have to 
date not been found in any ATRT-SHH. All SHH pathway 
marker genes overexpressed in this subgroup (such as 
GLI2) are thus most likely directly or indirectly activated 
by the SMARCB1 loss in these tumors as reported previ-
ously.24 Why SMARCB1 loss does not activate the SHH 
pathway to the same extent in the other subgroups re-
mains unknown but may be related to different cellular 
origins for these subgroups. Thus, whereas clear thera-
peutic indication for SHH pathway inhibitors has been es-
tablished for SHH MB, the role of vismodegib and other 
Smoothened inhibitors in ATRTs is unclear and remains 
to be further investigated.25
Genetically, ATRT-SHH cases differ from the other 2 sub-
groups regarding the type of SMARCB1 alterations. Most 
ATRT-SHH cases display compound heterozygous point 
mutations (P  <  0.00025, chi-square test) compared with 
the other groups (Fig.  4C), while homo- or heterozygous 
SMARCB1 deletions are less frequently found in this sub-
group compared with the other groups (66 from 134 sam-
ples, 44% in ATRT-SHH vs 77% in ATRT-TYR and 64% in 
ATRT-MYC) (Fig.  4D). With regard to age, ATRT-SHH rep-
resent a more intermediate subgroup (median age 20 mo, 
range 0–96), with patients on average younger than ATRT-
MYC patients and older than ATRT-TYR patients.
ATRT-SHH tumors can have either a supratentorial (56/68, 
75%) or infratentorial (30/68, 35%) localization (Fig.   4B). 
However, as reported previously,8 DNA methylation ana-
lyses suggest a further molecular heterogeneity within the 
ATRT-SHH subgroup. Indeed, when performing cluster ana-
lyses for ATRT-SHH profiles only, we find that the ATRT-SHH 
subgroup splits up in 2 subtypes associated with either a 
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mainly supratentorial location (ATRT-SHH-1) or a mainly 
infratentorial (ATRT-SHH-2) location (Supplementary Fig. 
7A, B). The split into 2 subtypes is supported by consensus 
clustering when analyzing the SHH subgroup separately 
(data not shown). It is important to note that both subtypes 
of ATRT-SHH express marker genes from the Notch and 
SHH pathways. More samples and analyses are needed to 
investigate whether there are other molecular or clinical 
differences between these 2 SHH subtypes. From a radi-
ological point of view, MRI analysis of ATRT-SHH tumors 
revealed that this is the only subgroup containing tumors 
that extend both infra- and supratentorially. Moreover, 
there was a lower degree of contrast enhancement in these 
tumors compared with ATRT-TYR and ATRT-MYC.19
With respect to in vivo models, the xenograft lines ATRT-
310FH and ATRT-311FH have been classified as ATRT-SHH 
and may thus represent a good tool for future studies.20 
Interestingly, a Rosa26CreERT2;Smarcb1flox/flox mouse model 
of rhabdoid tumors reported by Han et al develops spon-
taneous brain tumors, a subset of which have gene ex-
pression profiles very similar to that of human ATRT-SHH 
(shown in Supplementary Fig.  6A–C).12 Similarly, a Snf5 
Flox/Flox /p53 lox/lox /GFAP-Cre (as derived from the 
study by Ng et  al13) rhabdoid model seems to be closer 
to SHH than to the other subgroups. In general, devel-
opment of ATRT in murine models seems to require in-
activation of SMARCB1 during early embryonic (E6–E7) 
development, suggesting very early progenitors as cells 
of origin. Regarding in vitro models, the CHLA02, CHLA04, 
and CHLA05 cell lines all represent ATRT-SHH (formerly 
Group 1).7 Overexpressed drug targets that merit further 
investigation include the discoidin domain receptor tyro-
sine kinase 1 (DDR1), but also enhancer of zeste homolog 
2 (EZH2), which is a candidate drug target for ATRT in 
general.26 In vitro studies have shown that cell lines de-
rived from ATRT-SHH (Group 1) tumors are more sensitive 
to EZH2 inhibitors.7 Of note, recent epigenomic character-
izations of primary ATRT suggest that EZH2 overexpression 
in ATRT is not accompanied by global increase of re-
pressive mark H3K27me3,27 indicating that additional 
non-enzymatic functions of EZH2 may be important in 
ATRTs.28 Although promising preclinical data have fueled 
phase I trials using EZH2 inhibitors (eg, with tazemetostat, 
NCT02601937), it remains to be seen if this therapeutic reg-
imen will be efficacious in the clinical setting.
ATRT-MYC
The ATRT-MYC subgroup was named based on ele-
vated expression of the MYC oncogene as opposed to 
the MYCN oncogene, which is enriched in the ATRT-SHH 
group. However, different from other MYC or MYCN-
driven pediatric brain tumors like MB-Group 3, MB-SHH, 
and HGG-MYCN, MYC or MYCN amplifications have not 
been observed respectively in ATRT-MYC and ATRT-SHH 
tumors. In addition, one of the most striking mRNA ex-
pression patterns in these tumors is the overexpression 
of several HOXC cluster genes (Fig.  3B), driven by super 
enhancers8 (ie, very long stretched enhancers with abun-
dant H3K27-acetylation signal). Similar to ATRT-TYR, a 
broad categorization into neuronal and mesenchymal sub-
groups would assign these tumors a more mesenchymal 
expression profile.7 The typical genetic pattern that leads to 
SMARCB1 inactivation in these tumors is a homozygous, 
broad loss of SMARCB1 (which is present in 42/74 cases, 
57%), covering several hundred kilobases.7,8 In contrast to 
ATRT-TYR or ATRT-SHH tumors, point mutations are rare in 
ATRT-MYC tumors (Fig.  4C).
The median age of ATRT-MYC patients is significantly 
higher than in the 2 other subgroups (27 mo; range, 
0–190.9; Fig.  4A). This is mainly due to a number of older 
patients and not primarily due to a lack of very young pa-
tients in this subgroup.
Although a majority of ATRT-MYC tumors arise 
supratentorially (25/50, 50%), all spinal tumors in our co-
hort (6/50, 12%) were of the ATRT-MYC subgroup (Fig.  4B). 
MRI studies suggest ATRT-MYC tumors are distinguished 
by the presence of a strong peritumoral edema.19 Of note, 
recent reports have highlighted similarities between extra-
cranial malignant rhabdoid tumor (MRT) and ATRT-MYC 
on the DNA methylation level.29,30 As the DNA methyla-
tion profile of tumor entities is highly reflective of the cell 
of origin, it raises the questions of whether these entities 
share common cellular origins and whether the behavior 
of ATRT-MYC tumors may more closely resemble extracra-
nial rhabdoid tumors. Of note, recent studies of adult ATRT 
suggest that these fall mostly in the ATRT-MYC group and 
that further clinical and molecular heterogeneity in ATRT-
MYC may be revealed.28
We have shown here that several cell lines (BT12, 
BT16, CHLA266, CHLA06, SH) described by Torchia et  al7 
(Supplementary Fig.  6C, D) exhibit features more similar 
to the ATRT-MYC than to the ATRT-TYR subgroup. Several 
xenograft models of these cell lines suitable for in vivo drug 
testing have been reported.20,31 Our correlative analysis of 
genetically engineered mouse models and ATRT primary 
samples also revealed that as a subset of the published 
tumor samples generated from P0-CreC;Smarcb1 flox/flox, 
mice display high correlation with ATRT-MYC samples and 
may thus represent a model for the ATRT-MYC subgroup 
(Supplementary Fig.  6A, B).14
Given the previously mentioned similarities between 
ATRT-MYC and a subgroup of rhabdoid kidney tumors, 
common molecular targets between extracranial rhabdoid 
tumors and subgroups may exist. In fact, Oberlick et al32 
found indeed a dependency of both extracranial malig-
nant rhabdoid tumor and ATRT cell lines on a number of 
rhabdoid kidney tumors, thus highlighting novel drug tar-
gets in these tumors.
Discussion
Identification of distinct molecular subgroups in an oth-
erwise relatively genetically homogeneous disease has 
been a major step in further understanding the molec-
ular heterogeneity of ATRTs (Fig.  5).6–8,12 In this study we 
aimed to establish a consensus regarding the number of 
ATRT subgroups, their main molecular and clinical char-
acteristics, and a commonly accepted nomenclature in 
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order to enable a better understanding of the clinical 
heterogeneity in ATRTs. Here, we have shown that the 
3 molecular subgroups identified in previous studies 
based on DNA methylation and/or gene expression pro-
filing closely match with each other and a consensus 
was reached to name them ATRT-TYR, ATRT-SHH, and 
ATRT-MYC, according to the nomenclature published by 
Johann et al.8 The activated genes or pathways, which 
were chosen for this nomenclature, emerged when per-
forming overexpression analyses. However, their bi-
ological and therapeutic role in ATRT requires further 
investigation.
A consensus on number and naming of molec-
ular subgroups has in other entities, like MB,33 
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ependymoma,34 and glioblastoma,35 proven to be es-
sential for a uniform classification of patients’ tumor 
samples, subgroup-specific experiments using prop-
erly classified preclinical in vitro and in vivo models, 
and ultimately the design of clinical trials and patient 
stratification. A  further heterogeneity within these 
main 3 ATRT subgroups may still exist, similar to what 
has been reported for MB or ependymoma subgroups, 
for instance.36,37 Thus far, DNA methylation profiling 
has identified 2 further subtypes within the ATRT-
SHH subgroup, which correlates with predominant 
supratentorial (ATRT-SHH-1) or infratentorial (ATRT-
SHH-2) locations, but larger cohort studies are needed 
to better define molecular differences between these 
subtypes and whether they are clinically relevant.
As the outcome for ATRT patients is still relatively 
poor, new treatment strategies are urgently needed. 
Identification and characterization of ATRT subgroups 
may help discovery of subgroup-specific treatments, but 
will also help to elucidate new pan-ATRT therapies. Given 
the reported relatedness of ATRT-MYC to extracranial 
rhabdoids, these investigations should also include extra-
cranial malignant rhabdoid tumors such as those occurring 
in the kidney, liver, or other soft tissues.29,38 Additionally, 
more molecularly characterized models—including cell 
lines, patient-derived orthotopic xenograft models, and 
tumor organoid cultures—which represent the molecular 
spectrum of ATRTs are needed to critically advance ATRT 
therapeutics.
The prognostic value of the ATRT subgroups remains to 
be fully investigated. Torchia et al reported that ASCL1 pro-
tein expression, which is highly expressed in ATRT-SHH, 
was associated with a better outcome.6 However, it is not 
clear whether this is true for the whole SHH subgroup, as 
not all ATRT-SHH cases may express ASCL1. There clearly 
is a need for assessing the predictive power of the sub-
groups in well-characterized cohorts in prospective, clin-
ical studies.
Finally, to get a better understanding of the clinical 
relevance of ATRT subgroups, molecular subgrouping 
should be included in any future clinical trial for ATRT 
patients. The method of choice is currently DNA methyl-
ation profiling, as this requires very little input material 
(tumor DNA isolated from either frozen or formalin-fixed 
paraffin-embedded tumor tissue) and shows little or 
no bias when performed at different centers. However, 
as DNA methylation profiling may not always be avail-
able, it would still be helpful if more readily avail-
able markers or methods to subgroup ATRTs, such as 
immunohistochemical staining for tyrosinase or ASCL1, 
or Nanostring subgrouping methods, as have been de-
veloped for MB, could also be developed for broader use 
in clinical labs globally.
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Supplementary data are available at Neuro-Oncology 
online.
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